All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature

Based upon the clinical behavior of three patients, we suggest that the combination of low‐dose Ara‐C and all‐trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1‐mutated acute myeloid leukemia without FLT3 mutations, warrant...

Descripción completa

Detalles Bibliográficos
Autores principales: Forghieri, Fabio, Bigliardi, Sara, Quadrelli, Chiara, Morselli, Monica, Potenza, Leonardo, Paolini, Ambra, Colaci, Elisabetta, Barozzi, Patrizia, Zucchini, Patrizia, Riva, Giovanni, Vallerini, Daniela, Lagreca, Ivana, Marasca, Roberto, Narni, Franco, Venditti, Adriano, Martelli, Maria Paola, Falini, Brunangelo, Lo Coco, Francesco, Amadori, Sergio, Luppi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134148/
https://www.ncbi.nlm.nih.gov/pubmed/27980750
http://dx.doi.org/10.1002/ccr3.723
Descripción
Sumario:Based upon the clinical behavior of three patients, we suggest that the combination of low‐dose Ara‐C and all‐trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1‐mutated acute myeloid leukemia without FLT3 mutations, warranting perspective clinical studies in these selected patients.

Ejemplares similares